Retraction: Preparation of bioactive interferon alpha-loaded polysaccharide nanoparticles using a new approach of temperature-induced water phase/water-phase emulsion (Int J Nanomedicine, (2012), 7, (4841-4848), 10.2147/IJN.S35502);Preparation of bioactive interferon alpha-loaded polysaccharide nanoparticles using a new approach of temperature-induced water phase/water-phase emulsion

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4841-4848

  Liu, Guang ^a   Xu, Dong ^b   Jiang, Mier ^a   Yuan, Weien ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Activity of interferon alpha 2b; Dextran; Interferon alpha 2b; Nanoparticles; Stability of interferon alpha 2b

Indexed keywords

ALPHA2B INTERFERON; MACROGOL; NANOPARTICLE; POLYSACCHARIDE;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CYTOPATHOGENIC EFFECT; DRUG DELIVERY SYSTEM; FEMALE; FOLLICULAR LYMPHOMA; FREEZE DRYING; IN VITRO STUDY; LOW TEMPERATURE; LYMPHOMA CELL; NANOEMULSION; NONHUMAN; PARTICLE SIZE; RAT; SINDBIS VIRUS; ZETA POTENTIAL;

EID: 84870343839     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S170339     Document Type: Erratum

References (48)

1. Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Interferon alfa-2a for melanoma metastases. Lancet. 2002;359:978-979.
2. Legha SS, Papadopoulos NE, Plager C, etal. Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol. 1987;5:1240-1246.
3. Ramakrishna R, Manoharan A. Sustained long-term remissions with weekly interferon maintenance therapy in hairy cell leukemia. Asia Pac J Clin Oncol. 2010;6:210-212.
4. Bayraktar Y, Koseoglu T, Somner C, etal. The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B. J Viral Hepat. 1996;3:129-135.
5. Diwan M, Park TG. Stabilization of recombinant interferon-α by pegylation for encapsulation in PLGA microspheres. Int J Pharm. 2003; 252:111-122.
6. Tabata Y, Ikada Y. Synthesis of gelatin microspheres containing interferon. Pharm Res. 1989;6:422-427.
7. Yoshikawa Y, Komuta Y, Nishihara T, Itoh Y, Yoshikawa H, Takada K. Preparation and evaluation of once-a-day injectable microspheres of interferon alpha in rats. J Drug Target. 1999;6:449-461.
8. Degling L, Stjänkvist P, Sjöolm I. Interferon-gamma in starch microparticles: nitric oxide-generating activity in vitro and antileishmanial effect in mice. Pharm Res. 1993;6:783-790.
9. Castellanos IJ, Cuadrado WL, Griebenow K. Prevention of structural perturbations and aggregation upon encapsulation of bovine serum albumin into poly(lactide-co-glycolide) microspheres using the solid-in-oil-in-water technique. J Pharm Pharmacol. 2001;53:1099-1107.
10. Lu W, Park TG. Protein release from poly(lactic-co-glycolic acid) microspheres: protein stability problems. PDA J Pharm Sci Tech. 1995; 49:13-19.
11. Uchida T, Yagi A, Oda Y, Nakada Y, Goto S. Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres. Chem Pharm Bull. 1996;44:235-236.
12. Crotts G, Park TG. Stability and release of bovine serum albumin encapsulated within poly(lactide-co-glycolide) microparticles. J Control Release. 1997;44:123-134.
13. Lam XM, Duenas ET, Daugherty AL, Levin N, Cleland JL. Sustained release of recombinant human insulin-like growth factor-I for treatment of diabetes. J Control Release. 2000;67:281-292.
14. Blanco-Príeto MJ, Campanero MA, Besseghir K, Heimgatner F, Gander B. Importance of single or blended polymer types for controlled in vitro release and plasma levels of a somatostatin analogue entrapped in PLA/PLGA microspheres. J Control Release. 2004;96:437-448.
15. Sánchez A, Tobío M, González L, Fabra A, Alonso MJ. Biodegradable micro and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci. 2003;18:221-229.
16. Sinha VR, Trehan A. Biodegradable microspheres for protein delivery. J Control Release. 2003;90:261-280.
17. Yuan W, Wu F, Guo M, Jin T. Development of protein delivery microsphere system by a novel S/O/O/W multi-emulsion. Eur J Pharm Sci. 2009;36:212-218.
18. Muhrer G, Mazzotti M. Precipitation of lysozyme nanoparticles from dimethyl sulfoxide using carbon dioxide as antisolvent. Biotechnol Prog. 2003;19:549-556.
19. Yang S, Yuan W. Formulating protein therapeutics into particulate forms. Expert Opin Drug Deliv. 2009;6(10):1123-1133.
20. Kim J, Grate JW. Single-enzyme nanoparticles armored by a nanometer-scale organic/inorganic network. Nano Lett. 2003;3:1219-1222.
21. Costantino HR, Firouzabadian L, Hogeland K, etal. Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res. 2000;17:1374-1383.
22. Lavasanifar A, Samuel J, Kwon GS. Poly(ethylene oxide)-block-poly(l-amino acid) micelles for drug delivery. Adv Drug Deliv Rev. 2002;54:169-190.
23. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59:478-490.
24. Gu Z, Biswas A, Zhao M, Tang Y. Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev. 2011;40:3638-3655.
25. Jung S, Huh S, Cheon YP, Park S. Intracellular protein delivery by glucose-coated polymeric beads. Chem Commun. 2009;33:5003-5005.
26. Koker SD, Hoogenboom R, Geest BGD. Polymeric multilayer capsules for drug delivery. Chem Soc Rev. 2012;41:2867-2884.
27. Mukherjee B, Santra K, Pattnaik G, Ghosh S. Preparation, characterization and in-vitro evaluation of sustained release protein-loaded nanoparticles based on biodegradable polymers. Int J Nanomedicine. 2008;3:487-496.
28. Ma W, Chen M, Kaushal S, etal. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine. 2012;7:1475-1487.
29. Binsalamah ZM, Paul A, Khan AA, Prakash S, Shum-Tim D. Intramyocardial sustained delivery of placental growth factor using nanoparticles as a vehicle for delivery in the rat infarct model. Int J Nanomedicine. 2011;6:2667-2678.
30. Tan Q, Tang H, Hu J, etal. Controlled release of chitosan/heparin nanoparticle-delivered VEGF enhances regeneration of decellularized tissue-engineered scaffolds. Int J Nanomedicine. 2011;6:929-942.
31. Taluja A, Youn YS, Bae YH. Novel approaches in microparticulate PLGA delivery systems encapsulating proteins. J Mater Chem. 2007;17: 4002-4014.
32. Lee JS, Lu Y, Baer GS, Markel MD, Murphy WL. Controllable protein delivery from coated surgical sutures. J Mater Chem. 2010;20:8894-8903.
33. Shinde UP, Joo MK, Moon HJ, Jeong B. Sol-gel transition of PEG-PAF aqueous solution and its application for hGH sustained release. J Mater Chem. 2012;22:6072-6079.
34. Ren T, Yuan W, Zhao H, Jin T. Sustained-release polylactide-co-glycolide microspheres loaded with pre-formulated protein polysaccharide nanoparticles. Micro and Nano Lett. 2011; 6 (2):70-74.
35. Yuan W, Liu Z. Controlled-release and preserved bioactivity of proteins from (self-assembled) core-shell double-walled microspheres. Int J Nanomedicine. 2012;7:257-270.
36. Yuan W, Liu Z. Surgical wound healing using hemostatic gauze scaffold loaded with nanoparticles containing sustained-release granulocyte colony-stimulating factor. Int J Nanomedicine. 2011;6:3139-3149.
37. Jin T, Zhu J, Wu F, Yuan W, Geng LL, Zhu H. Preparing polymer-based sustained-release systems without exposing proteins to water-oil or water-air interfaces and cross-linking reagents. J Control Release. 2008;128:50-59.
38. Zaslavsky BY. Aqueous Two-Phase Partitioning: Physical Chemistry and Biological Applications. New York: Marcel Dekker; 1995.
39. Gomi K, Morimoto M, Nakamizo N. Characteristics of antiviral and anticellular activities of human recombinant interferon-gamma. Jpn J Cancer Res. 1985;76:224-234.
40. Cleland JL, Jones JS. Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharm Res. 1996;13:1464-1475.
41. Breen ED, Curley JG, Overcashier DE, Hsu CC, Shire SJ. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm Res. 2001;18:1345-1353.
42. Yoshioka S, Aso Y, Kojima S. Dependence of the molecular mobility and protein stability of freeze-dried gamma-globulin formulations on the molecular weight of dextran. Pharm Res. 1997;14:736-741.
43. Yuan W, Wu F, Geng Y, Xu S, Jin T. Preparation of dextran glassy particles through freezing-induced phase separation. Int J Pharm. 2007;339(1-2): 76-83.
44. Yuan W, Geng Y, Wu F, etal. Preparation of polysaccharide glassy microparticles with stabilization of proteins. Int J Pharm. 2009; 366:154-159.
45. Xu D, Hu A, Su J, Wu F, Yuan W. Micro and nanotechnology for intracellular delivery therapy protein. Nano-Micro Lett. 2012;4:118-123.
46. Yuan W, Wu F, Geng Y, Xu S, Jin, T. An effective approach to prepare uniform protein-Zn2+ nanoparticles under mild conditions. Nanotechnology. 2007;18 (14): no. 145601.
47. Yuan W, Zhang Y, Wu F, et al. Preparation of protein-loaded sustained-release microspheres via 'solid-in-oil-in-hydrophilic oil-in-ethanol (S/O/hO/E)' emulsification. Colloids Surf B Biointerfaces. 2010;79(2):326-333.
48. Rong X, Mo X, Ren T, et al. Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats. Eur J Pharm Sci. 2011;43(4):334-342.